This message contains images. If you don't see images, click here to view.
Advertise in this news brief.




Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           July 01, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store

 

ACOG updates recommendations to include 9-valent HPV vaccine
Medscape (Free login required)
A key role of obstetrician/gynecologists and other healthcare providers is to provide patients and their parents with information on the benefits and safety of the human papillomavirus (HPV) vaccine and to encourage adolescents to receive the HPV immunization, according to updated recommendations published online by the American College of Obstetricians and Gynecologists. ACOG updated its March 2014 recommendations to include the new 9-valent HPV vaccine, also recommended by the Centers for Disease Control and Prevention (CDC) for girls and boys aged 11 to 12 years. Those who do not receive the HPV vaccine during the target age range should undergo catch-up vaccination until age 26 years.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE  




SGO NEWS


Update SGO member status by July 31
Are you graduating from your Fellowship program? Starting your residency? Ensure you update your membership status so you can continue to receive all of your valuable SGO benefits. Transitioning SGO members need to update their member status by Friday, July 31. Online application forms for all eight membership levels are available on sgo.org.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


OVARIAN CANCER


Bevacizumab with chemo improves survival in ovarian cancer with poor prognosis
Gynecologic Cancer Advisor
When bevacizumab was added to standard chemotherapy, the patients with a poor prognosis of ovarian cancer had an overall survival benefit, according to the ICON7 study published online this week in journal The Lancet Oncology. An international, phase 3, two-arm, open-label study included 1,528 women with newly diagnosed ovarian cancer, high-risk early-stage disease or more advanced disease, and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. The study was funded by the National Institute for Health Research through the U.K. National Cancer Research Network, the Medical Research Council, and Roche.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Advertisement
PRODUCT SHOWCASE
  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.
 


GUIDELINES


ACP recommends less cancer screening for average-risk adults
Healio
The American College of Physicians released clinical guidelines for screening average-risk adults without symptoms for several common cancers. An ACP High-Value Care Task Force compiled the guidelines, which focused primarily on breast, colorectal, ovarian, prostate and cervical cancers. For cervical cancer, ACP recommended that average-risk patients aged older than 21 years should still be screened by cytology every 3 years, but that once they reach age 30 years, they can have the option to maintain that schedule or switch to screening every 5 years with the addition of HPV testing. The guidelines also recommended against screening for average-risk women aged younger than 21 years, HPV testing for women aged younger than 30 years, biannual pelvic exams to screen for cervical cancer, and screening after a hysterectomy or cervical cancer treatment. The ACP recommended against ovarian cancer screening for all average-risk women due to a lack of evidence of benefit coupled with increase in harm and cost.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


BREAST CANCER


PALB2 mutations may increase risk for breast cancer mortality
Healio
Women harboring a PALB2 mutation face an increased risk for breast cancer and a potentially increased risk for breast cancer mortality compared with non-carriers, according to the results of a prospective cohort study. Previous research has indicated PALB2 mutations predispose women for breast cancer. However, the effect of PALB2 mutations on disease prognosis remained unknown, according to study background.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Top takeaways from ASCO: Breast cancer
Healio
Physicians managing patients with various breast cancer diagnoses left ASCO 2015 with new data to consider when making decisions every day — some practice-changing, others potentially so. Key opinion leaders offer their views on positive results from trials investigating an adjunct endocrine therapy, an aromatase inhibitor as an option to tamoxifen, a novel chemotherapy and bisphosphonates.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




SURVIVORSHIP


To recur, to sleep: There's a rub for cancer survivors
Medscape (Free login required)
Cancer survivors often fear disease recurrence, and this can affect the quality of their sleep, according to a new report. In a survey of 67 cancer survivors, 52 percent reported poor sleep quality during the previous month. People with some college education and those more afraid of a recurrence appeared to be at greater risk for poor sleep. The survey results were published in the June issue of the Journal of Psychosocial Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


MISSED AN ISSUE OF WOMEN'S CANCER NEWS?
Visit the SGO Women's Cancer News archive page.


HEALTH POLICY


Senate panel advances spending bill that chips away at Obamacare
The Hill
The Senate Appropriations Committee on June 25 advanced a nearly $153.2 billion bill that chips away at Obamacare, just after the Supreme Court upheld a critical portion of the healthcare law. It marks the first time the full committee reported the measure in two years. “This bill prioritizes programs that will provide a significant benefit to all Americans including providing the National Institutes of Health with a $2 billion increase to focus on advancing medical treatments, Precision Medicine and research to find a cure for Alzheimer's and cancer,” said Sen. Roy Blunt (R-Mo), the chairman of the subcommittee that oversees the bill.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


 



Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news


Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

June 24, 2015
June 17, 2015
June 17, 2015
June 10, 2015






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063